Top Pharmaceuticals Companies in Malaysia

The Pharmaceuticals industry is a crucial component of Malaysia's economy, contributing significantly to its gross domestic product (GDP) and providing essential healthcare products to its citizens. In 2022, the industry is expected to maintain its growth trajectory and continue to be a major contributor to the country's economic growth.

read full article below
Filter bySearch by company name, registration number or domain name
CompanyHeadcountContactDescriptionDecision Maker
ZYDUS GROUP10,582

MCLINICA207

LONZA15,346 +65 6521 4362

At Lonza, we enable #AHealthierWorld by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people.In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of.Our work makes #AMeaningfulDifference.

EP PLUS GROUP101 +60 3-6205 2728

Established since 1997, EP Plus Group has grown extensively to become a group of highly experienced and skilled pharmaceutical and aesthetic marketeers, specializing in unique European brands. Today, we are a leading industry player on a rolling mission to be the most desired, innovative, leading regional medical marketing brand. We believe that our continuous success and growth stem from our people and we could not be more thankful. And as we go further, we would love for you to join us on this exciting journey and together, we strive for excellence. Feel free to drop us a line or talk to us at hr@epplusgroup.com to learn about our career opportunities.For more information on EP Plus Group, visitWebsite: www.epplusgroup.comFacebook: www.facebook.com/epplusgroup

HALIM BIOTECH PTE LTD10 +65 6848 8010

Halim Biotech Pte Ltd is a company based in Singapore.

MP BIOMEDICALS616 +65 6775 0008

MP Biomedicals is dedicated to giving scientists and researchers innovative, quality tools and superior service to aid them in their quest for ground-breaking discovery and turning the hope for life-changing solutions into a reality.The company manufactures and sells more than 55,000 products and is one of the only companies in the industry to offer a comprehensive line of life science, fine chemical and diagnostic products. MP Biomedicals is a world-wide corporation, with ISO-certified and FDA-approved manufacturing and distribution facilities throughout the globe and headquartered in Southern California. A vast network of global distributors and satellite facilities and offices throughout Europe, Asia, Australia and the Americas assures customers top quality products delivered when and where needed.No matter how dynamic the evolution of the life science and biotechnology markets, we remain committed to supporting our customers in their efforts to make new discoveries. From basic research, through scale-up, to full-scale production and diagnostic testing, MP Biomedicals serves every industry need – from specialized areas of research to supplying large scale quantities of fine chemicals. Our customers partner with us because they want a long-time player and reliable colleague in the fields of life science research and diagnostics. MP Biomedicals will never rest in our odyssey to remain at the forefront of discovery in the ever-changing biomedical industry.

ORIENT EUROPHARMA CO., LTD194 +65 6339 8820

Orient Europharma. Co., Ltd. Headquartered in Taipei, Taiwan, is a specialty pharmaceutical company focused in commercialization of our partner’s product. Our current partners in the region includes the following: Almirall, Chiesi, Elan, Pfizer, Kissei, NaonCarrier, Pierre Fabre, , Recordati, Q-med & UCB.In 2010, We stands among top 30 pharmaceutical companies in both Taiwan and Philippines based on IMS survey. Our sales turnover was over $125 million U.S. dollars, and our business incorporates not only sales, also the manufacturing (with two large manufacturing plants), marketing, and distribution of ethical and OTC products. With Subsidiaries across Hong Kong, Malaysia, Singapore, Philippines and a strong sales network of 360 dedicated and experienced sales representatives, we have the ability and expertise to introduce our partners’ product in the South East Asia Region. Orient Europharma. Co. is a fully-integrated research, production and sales organization. Our key of success lays on our employee’s enthusiasm and professionalism who took pride in their in day to day work knowing their contribution makes a difference to patients.

RINEU (M) SDN BHD6 +60 3-2701 6345

YOUR SKIN. YOUR BEAUTY.Our skin makes up 16% of our body weight, making it our largest organ. Now with 16PERCENT, a dermatology-based skincare range, sensitive skin can be uniquely hydrated and protected. Curated by Dr. Nazirin Ariffin, a dermatologist with more than 20 years of experience, and guided by years of treating patients with plethora of skin concerns, the 16PERCENT range is safe and will work perfectly with your skin to ensure that your skin is forever glowingly healthy.

AMILI52 +65 6977 7199

AMILI is a precision gut microbiome company based in Singapore, serving the region. Through AMILIs proprietary analytics engine, PRIME, we develop diagnostics tests, predictive algorithms and microbiome-modifying interventions. Our consumer health arm, BIO & ME, utilises insights from AMILIs database and PRIME to generate Asia-centric solutions towards personalised diet, supplementation and precision health. AMILI also houses Southeast Asias first and only gut microbiome bank for clinical use and research. For more information, visit www.amili.asia.

CSI MEDICAL RESEARCH PTE LTD11 +65 9832 5230

We are a home grown, Singapore based and registered Clinical Research Organisation (CRO) with intent to provide clinical trials related service offerings to our customers.CSI Medical Research (CSI MR) have extensive and applicable local knowledge of key workflows both in investigators sites and from sponsors. Given the Singapores government huge endorsement on clinical research, both in resources and financial support, we believe segments like early phases for home grown IPs, Investigator Initiated trials remains hugely under served by CRO industry.  CSI MR aims to answer this call to support these important segments and is determined to utilize our industry experience to provide good quality, customized and cost effective services. We are also focusing of bringing innovative ideas and automation into clinical trials. The goal is to remove process wastes and streamlining the focus of stakeholders to patient safety and data integrity.CSI MR VisionA preferred partner that provides cost effective and customized clinical solutions to our customers in their quest for scientific enhancement. Leveraging technology to modernize clinical solutions that enables desired outcomesCSI MR Mission•    Ensure safety of patients participating in Investigators Initiated Trials (IIT) and clinical trials that we managed•    Strive to provide flexible solutions while focusing on the needs of our customers

MPS YOUNG PHARMACISTS CHAPTER44 +60 3-8079 1861

About MPS and MPS-YPC:Since it was first established in 2007, the Malaysian Pharmacists Society - Young Pharmacists Chapter (MPS-YPC) is a prominent chapter under the umbrella of MPS. It is a non-for-profit, vibrant young pharmacist-run organization which has been actively envisioning a professional body which represents young pharmacists from all sectors, be it public, private, industrial, hospital, community, or even non-traditional fields involving pharmacists. Acknowledging the key role of MPS in advancing pharmacy practice in Malaysia, MPS-YPC is one of the major providers of continuing professional development (CPD) programmes. This is done by actively engaging young pharmacists through a series of talks, conferences and dialogues pertaining to the latest updates and trends in the industry.Vision of MPS-YPC :To bring together young pharmacists across the nation to shape the future of pharmacy and healthcare in Malaysia. Mission of MPS-YPC: ● To promote and strengthen the ties between young pharmacists through networking activities. ● To provide young pharmacists with a channel to air their professional concerns and to express their views on pharmacy and health related issues. ● To instil a sense of pride in the pharmacy profession. ● To promote excellent pharmacy practice that reflects the highest degree of professionalism and ethical conduct. ● To uplift the image and perception of pharmacy profession amongst the public and fellow healthcare professionals. ● To nurture and develop future healthcare leaders.

Top Pharmaceuticals Companies in Malaysia

Key Statistics from 2022

According to the Ministry of Health Malaysia, the pharmaceuticals industry's total revenue in 2022 is projected to reach RM 14.5 billion, a 6.5% increase from the previous year. The industry's contribution to Malaysia's GDP is expected to grow to 1.3% in 2022, up from 1.2% in 2021. The industry is also projected to create around 25,000 new jobs in 2022, a testament to its resilience and ability to adapt to changing market conditions.

Factors Contributing to Growth and Success

Several factors have contributed to the growth and success of the Pharmaceuticals industry in Malaysia. One significant factor is the government's commitment to enhancing healthcare services in the country. The Malaysian government has launched various initiatives aimed at improving healthcare access and promoting the development of the pharmaceuticals industry, such as the National Pharmaceuticals Policy and the Malaysian Health Data Warehouse.

Moreover, the government has also introduced policies and incentives to encourage private sector investment in the industry. These policies include tax incentives and the development of the Malaysian Biotechnology Corporation, which aims to develop and promote the biotechnology industry in Malaysia.

Industry Growth and Comparison to Previous Years

The Pharmaceuticals industry in Malaysia has shown remarkable growth in recent years. According to the Malaysian Investment Development Authority, the industry's total approved investments have increased by an average of 4.5% per annum over the last five years. The sector has also been a significant contributor to Malaysia's economic growth, with its contribution to GDP increasing from 1.0% in 2015 to 1.2% in 2021.

Key Trends: Technological Disruptions

The Pharmaceuticals industry in Malaysia is also witnessing several technological disruptions that are changing the way businesses operate and develop new drugs. One significant trend is the use of digital platforms to conduct clinical trials and monitor patient outcomes. Digital platforms can enhance efficiency, reduce costs, and improve patient safety.

Another technological trend in the industry is the use of precision medicine and personalized healthcare. Precision medicine involves tailoring medical treatment to an individual's genetic makeup, medical history, and lifestyle, which can enhance treatment efficacy and reduce side effects.

Challenges

The Pharmaceuticals industry in Malaysia is a vital component of its economy, contributing significantly to its GDP and providing essential healthcare products to its citizens. The industry has shown remarkable growth in recent years, driven by government initiatives, private sector investment, and technological disruptions. However, the industry also faces significant challenges, such as increasing competition from other countries in the region and the shortage of skilled talent. Nevertheless, the industry is expected to maintain its growth trajectory and play a crucial role in Malaysia's economic development.

Future Outlook

Looking ahead, the Pharmaceuticals industry in Malaysia is expected to continue its growth trajectory, driven by the government's commitment to enhancing healthcare services and private sector investment. The industry is also likely to witness further technological disruptions, which will enable greater efficiency, collaboration, and innovation.

To stay ahead of the curve, the Pharmaceuticals industry in Malaysia must continue to innovate and adapt to changing market conditions. The industry must also work towards developing a skilled workforce that can support the industry's growth and ensure that businesses have access to the talent they need to innovate and succeed in the global marketplace.

One significant opportunity for the Pharmaceuticals industry in Malaysia is the growing demand for personalized healthcare and precision medicine. Consumers are increasingly demanding that healthcare providers and pharmaceutical companies offer personalized treatment options that cater to their specific needs and medical history. To leverage this opportunity, pharmaceutical companies operating in Malaysia must invest in research and development to develop new drugs that are tailored to individual patients.

Moreover, pharmaceutical companies must also work towards improving drug accessibility and affordability to cater to Malaysia's diverse population. This approach can enhance patient outcomes, improve treatment efficacy, and reduce the burden on Malaysia's healthcare system.

Conclusion

In conclusion, the Pharmaceuticals industry in Malaysia is a thriving and resilient sector that is expected to continue its growth trajectory in the coming years. The industry's success can be attributed to government initiatives, private sector investment, and technological disruptions. However, the industry also faces challenges such as increasing competition from other countries in the region and the shortage of skilled talent. To stay ahead of the curve, the industry must continue to innovate and adapt to changing market conditions. Moreover, pharmaceutical companies operating in Malaysia must invest in research and development to develop new drugs that cater to individual patients and work towards improving drug accessibility and affordability. By doing so, the industry can continue to enhance healthcare services, drive economic growth, and create job opportunities for Malaysians.

undefined's picture
By Melissa Goh
Published on 22 May 2023